Novo Nordisk Submits CagriSema for FDA Review as a Once-weekly GLP-1–amylin Combination Therapy for Weight Management
Novo Nordisk has officially filed a New Drug Application (NDA) with the U.S. FDA for CagriSema, a once-weekly subcutaneous injection intended for chronic weight management. CagriSema represents a significant technological leap in the incretin space, combining the established GLP-1 receptor agonist semaglutide (the active ingredient in Wegovy) with cagrilintide, a long-acting amylin analog. While semaglutide primarily targets appetite suppression and gastric emptying through the GLP-1 pathway, cagrilintide acts on the amylin receptors to enhance sati...
